# Psychiatrist.com > Psychiatrist.com is the online home of The Journal of Clinical Psychiatry (JCP) and The Primary Care Companion for CNS Disorders (PCC), peer-reviewed journals published by Physicians Postgraduate Press, with clinical news, Insights and CME for psychiatrists and primary care clinicians. Content is written for clinicians. Journal articles are peer reviewed; news and Insights are editorial. Each article page carries schema.org structured data (ScholarlyArticle, NewsArticle or Article) with authors, dates and references. Full URL list: https://www.psychiatrist.com/sitemaps/index.xml ## Journals - [The Journal of Clinical Psychiatry](https://www.psychiatrist.com/jcp/): peer-reviewed research in clinical psychiatry - [The Primary Care Companion for CNS Disorders](https://www.psychiatrist.com/pcc/): peer-reviewed research at the intersection of primary care and psychiatry ## Sections - [News](https://www.psychiatrist.com/news/): clinical news and coverage for psychiatry and neurology - [Insights](https://www.psychiatrist.com/insights/): editorial syntheses and Clinical Pearls built on the journals ## Recent news - [Non-Drug Treatment Landscape for GAD: Cognitive Therapies](https://www.psychiatrist.com/news/gad-non-drug-treatment-cognitive-therapies/): CBT has the strongest evidence among cognitive therapies for GAD, while support for applied relaxation and metacognitive therapy is less certain. - [GAD Is More Common in Women, but Evidence Around Pregnancy and Menopause Remains Unclear](https://www.psychiatrist.com/news/gad-women-pregnancy-menopause-evidence-unclear/): GAD is more common in women, but evidence that pregnancy or menopause alters GAD itself remains limited because studies mostly measured anxiety symptoms. - [Negative Symptoms and Xanomeline-Trospium: What Trials and Practice Data Can and Cannot Show](https://www.psychiatrist.com/news/xanomeline-trospium-negative-symptom-scores-pooled-schizophrenia-trials/): Negative-symptom scores fell on xanomeline-trospium in schizophrenia trials, but how much reflects treatment, especially in stable illness, remains unclear. - [Larger Response in Prominent Negative Symptoms, but No Evidence of Superiority](https://www.psychiatrist.com/news/xanomeline-trospium-negative-symptom-severity-schizophrenia/): Xanomeline-trospium shows activity against negative symptoms of schizophrenia, but current evidence does not establish superiority over other antipsychotics. - [Two Investigational Paths in GAD: Company-Reported Results on DT120 ODT and SNTX-2643](https://www.psychiatrist.com/news/gad-company-reported-results-dt120-odt-sntx-2643/): DT120 (lysergide) and SNTX-2643 are advancing as investigational GAD treatments at different stages of development, with neither yet approved by the FDA. - [Generalized Anxiety Disorder After 65: What the Screening Evidence Does and Does Not Cover](https://www.psychiatrist.com/news/generalized-anxiety-disorder-after-65/): Anxiety screening in adults 65 and older lacks sufficient evidence, as data on GAD screening tool accuracy and treatment effectiveness remain limited. - [A Recovery Estimate Reflects Symptoms and Function, Not What the Patient Reports](https://www.psychiatrist.com/news/schizophrenia-recovery-estimates-symptom-functional-appraisal/): Schizophrenia recovery rates vary by outcome type; a 50-sample meta-analysis found 13.5% median recovery using stringent symptom and functional criteria, excluding appraisal measures. - [A Rising Quality of Life Score Does Not Mean Improved Function](https://www.psychiatrist.com/news/quality-of-life-scores-mood-function-schizophrenia/): Quality of life scores in schizophrenia track mood more closely than function; depression alone explained 23% of variance in self-reported social functioning. - [Who Gets Excluded from Psychedelic Trials in GAD, and Why](https://www.psychiatrist.com/news/psychedelic-trials-generalized-anxiety-disorder-exclusion-criteria/): Psychedelic trials in generalized anxiety disorder exclude participants based on cardiac risk from 5-HT2B agonism, personal and family psychiatric history, and psychotropic washout requirements. - [Measurement-Based Care in Generalized Anxiety Disorder](https://www.psychiatrist.com/news/measurement-based-care-generalized-anxiety-disorder/): Measurement-based care in GAD rests on validated tools and guideline timepoints, but no trial has yet isolated the effect of measurement itself. - [Similar Outcomes With 2-Week and 4-Week Tapers to Xanomeline-Trospium](https://www.psychiatrist.com/news/xanomeline-trospium-antipsychotic-taper-schizophrenia-outcomes/): Xanomeline-trospium 2-week and 4-week taper schedules show similar discontinuation rates and tolerability in stable schizophrenia; 86% reached target dose. - [Xanomeline-Trospium and EPS: Low Rates Across Trials, Comparative Data Remain Limited](https://www.psychiatrist.com/news/xanomeline-trospium-eps-emergent-trials-motor-safety/): Xanomeline-trospium EPS rates were low across EMERGENT-1, -2, and -3, but trial limitations, attrition, and no comparator data leave the motor safety profile incompletely defined. - [Improved but Not Recovered: The Relapsing Course of Generalized Anxiety Disorder](https://www.psychiatrist.com/news/gad-relapsing-course-remission-recurrence-long-term-management/): GAD follows a chronic, relapsing course in which comorbidity reduces recovery odds and antidepressant discontinuation roughly triples relapse risk. - [Safety Across Classic Psychedelics in GAD: What Three Investigational Programs Show So Far](https://www.psychiatrist.com/news/safety-classic-psychedelics-gad-investigational-programs/): Early safety data from lysergide, psilocybin, and deuterated DMT GAD trials show predominantly mild-to-moderate, session-concentrated adverse events across all three programs. - [The Weakened Brake: Circuit and Synaptic Biology in Generalized Anxiety Disorder](https://www.psychiatrist.com/news/gad-amygdala-prefrontal-circuit-plasticity/): GAD reframed as a disorder of maladaptive synaptic and circuit plasticity, linking amygdala-prefrontal dysregulation to slow treatment response and relapse. - [The Receptor at the Center of Psychedelic Therapies for GAD](https://www.psychiatrist.com/news/5-ht2a-receptor-mechanism-psychedelic-therapies-gad/): Classic psychedelics target 5-HT2A receptors, not serotonin transporters. Slow dissociation and intracellular signaling may explain lasting effects seen in GAD. - [2026 Congress Coverage: The Persistence Problem in GAD and Treatment-Resistant Depression](https://www.psychiatrist.com/news/gad-treatment-resistant-depression-2026-congress-coverage/): Real-world GAD claims data show 18% treatment persistence at one year; TRD Phase 3 baseline data reveal severe, chronic illness after multiple failed pharmacotherapy trials. - [Psychedelics Are Advancing in GAD, but None Are Yet Approved](https://www.psychiatrist.com/news/psychedelics-advancing-gad/): Two psychedelics show early GAD trial signals—DT120 and psilocybin—but no agent is approved for anxiety. Interpreting evidence by stage, not label, matters - [How Generalized Anxiety Disorder Presents, and Why It Is Often Missed](https://www.psychiatrist.com/news/generalized-anxiety-disorder-recognition-clinical-practice/): GAD frequently presents with somatic symptoms, leading to missed diagnoses; only 34% of cases are correctly identified in primary care, with a median 9-year treatment delay. - [Generalized Anxiety Disorder: A Persistent Burden Despite Standard Treatments](https://www.psychiatrist.com/news/generalized-anxiety-disorder-persistent-burden/): GAD affects ~20M US adults, yet one-third achieve remission with first-line SSRIs/SNRIs and no new mechanism has been approved since 2007; the treatment gap persists. - [Why Your Psychiatric Patients Aren’t Sleeping: CBT-I and a Pathway That Finally Works](https://www.psychiatrist.com/news/why-your-psychiatric-patients-arent-sleeping-cbt-i/): Untreated sleep disorders complicate psychiatric outcomes. Explore CBT-I, CPAP, and oral appliance therapy to address the sleep evaluation gap. - [The Sleep Disorder You Are Missing in Your Psychiatric Patients & The Modern Solution For It](https://www.psychiatrist.com/news/the-sleep-disorder-you-are-missing-in-your-psychiatric-patients/): Sleep disorders are frequently overlooked in psychiatric care. Explore why sleep screening matters and how home sleep testing improves diagnosis and treatment. - [Brain Training Could Delay Dementia for Years](https://www.psychiatrist.com/news/brain-training-could-delay-dementia-for-years/): A new study suggests that brief, targeted speed-of-processing brain training might curb dementia risk by about a quarter over two decades. - [Psychosis Soars in Younger Generations](https://www.psychiatrist.com/news/psychosis-soars-in-younger-generations/): A large study finds that psychosis diagnoses are rising sharply – and appearing earlier – among younger generations. - [Ketogenic Diet Shows Modest Mental Health Benefits](https://www.psychiatrist.com/news/ketogenic-diet-shows-modest-mental-health-benefits/): New research suggests ketogenic diets may deliver modest, short-term antidepressant benefits. But they’re no cure and hard to sustain. ## Recent Insights - [Cannabis Use and Early Psychiatric Rehospitalization in Young Adults With Bipolar or Psychotic Disorders](https://www.psychiatrist.com/insights/cannabis-use-and-early-psychiatric-rehospitalization-in-young-adults-with-bipolar-or-psychotic-disorders/): Justine Perino, MD, discusses a historical cohort study assessing whether cannabis use at admission is associated with psychiatric rehospitalization after discharge in young adults with bipolar or psychotic disorders. T… - [Negative Symptoms May Predict Who Responds to Xanomeline-Trospium in Schizophrenia](https://www.psychiatrist.com/insights/negative-symptoms-schizophrenia/): Mike Halassa describes negative symptoms in schizophrenia and discusses clinical and post-hoc evidence that potentially suggests negative symptoms may be a useful clinical feature to look for when considering xanomeline… - [Metabolic and Prolactin Outcomes After 52 Weeks of Xanomeline-Trospium](https://www.psychiatrist.com/insights/metabolic-and-prolactin-outcomes-after-52-weeks-of-xanomeline-trospium/): Metabolic, lipid and prolactin outcomes after 52 weeks of open-label xanomeline-trospium in 566 adults with schizophrenia (EMERGENT-5). - [Combining Clozapine and Xanomeline/Trospium Chloride: Mechanisms of Action and the Genesis of Catatonia](https://www.psychiatrist.com/insights/combining-clozapine-and-xanomeline-trospium-chloride-mechanisms-of-action-and-the-genesis-of-catatonia/): Warren Cheng, MD Candidate, on a case where abruptly stopping clozapine while continuing Cobenfy (xanomeline-trospium) preceded severe catatonia, and the rebound-cholinergic hypothesis that may explain the risk as Coben… - [The Reported Strength of Association Between Symptoms and Quality of Life Depends on How Quality of Life Is Defined and Measured](https://www.psychiatrist.com/insights/symptoms-quality-of-life-schizophrenia/): Symptoms correlate modestly with quality of life in schizophrenia, but the reported strength depends on the measure. Pooled findings from 56 studies. - [Population Pharmacokinetics and Dosing Simulations for Paliperidone Palmitate 351 mg as Alternative Maintenance Doses in Patients With Schizophrenia or Schizoaffective Disorder](https://www.psychiatrist.com/insights/population-pharmacokinetics-and-dosing-simulations-for-paliperidone-palmitate-351-mg-as-alternative-maintenance-doses-in-patients-with-schizophrenia-or-schizoaffective-disorder/): Jonathan M. Meyer, MD, and Leslie Citrome, MD, present a JCP video abstract on pharmacokinetic simulations for paliperidone palmitate 351 mg, and what its every-4, -6, and -8-week dosing options could mean for schizophr… - [Switching From Oral Atypical Antipsychotics to Xanomeline-Trospium in Schizophrenia](https://www.psychiatrist.com/insights/switching-oral-atypical-antipsychotics-xanomeline-trospium-schizophrenia/): A Clinical Pearl on switching patients from oral atypical antipsychotics to xanomeline-trospium: 2- vs 4-week taper data and panel guidance. - [Differentiating Bipolar Spectrum Disorders From Other Psychiatric Disorders With Shared Features](https://www.psychiatrist.com/insights/differentiating-bipolar-spectrum-disorders-from-other-psychiatric-disorders-with-shared-features/): Mohamed Soliman, MD, on why bipolar disorder often hides inside familiar symptoms, the four questions that reveal the underlying pattern, and how to choose the right screening tool for your setting. - [What's Next for PPD Treatment | Inhaled Mebufotenin (GH001) Phase 2a Results](https://www.psychiatrist.com/insights/whats-next-for-ppd-treatment-inhaled-mebufotenin-gh001-phase-2a-results/): Kristina Deligiannidis, MD, presents phase 2a results for inhaled GH001 (mebufotenin), a psychedelic-based therapeutic that produced same-day remission of postpartum depression in an open-label trial, with rapid clearan… - [Does TMS Work for Depression? What Clinicians Should Know](https://www.psychiatrist.com/insights/does-tms-work-for-depression-what-clinicians-should-know/): An overview from Andrew Van Der Vaart, MD, on who responds to transcranial magnetic stimulation for depression, how it works, and how the standard, theta-burst, and SAINT protocols differ. - [Menopausal Mood and Anxiety Disorders: Treatment Options and the Role of Hormone Therapy](https://www.psychiatrist.com/insights/menopausal-mood-and-anxiety-disorders-treatment-options-and-the-role-of-hormone-therapy/): An increasing number of women are presenting with menopausal depression and anxiety — and questions about hormone therapy. Dr. Ruta Nonacs covers the risk factors, treatment options, and the role of menopausal hormone t… - [Predicting Postpartum Depression: Epigenetic Biomarkers and the Future of Prevention](https://www.psychiatrist.com/insights/predicting-postpartum-depression-epigenetic-biomarkers-and-the-future-of-prevention/): Postpartum depression is one of the leading causes of maternal mortality in the United States. Dr. Jennifer Payne shares research identifying epigenetic biomarkers that can predict who is at risk, from a blood test take… - [Maternal Mental Health: Postpartum Depression, Postpartum Psychosis, and the Work Ahead](https://www.psychiatrist.com/insights/maternal-mental-health-postpartum-depression-postpartum-psychosis-and-the-work-ahead/): Postpartum depression remains the most common complication in modern obstetrics, yet the majority of patients do not get effective treatment. Dr. Lee Cohen reflects on the progress made in perinatal psychiatry and how f… - [The Tyranny of the P-Value](https://www.psychiatrist.com/insights/the-tyranny-of-the-p-value/): P-values don't tell us everything we need to know. Dr. Leslie Citrome explains why the P-value is not the same as an effect size — and why you need both to assess what a clinical trial actually found. - [What Is Meant by "Deprescribing," and Does It Belong in Our Lexicon?](https://www.psychiatrist.com/insights/what-is-meant-by-deprescribing-and-does-it-belong-in-our-lexicon/): Dr. Joseph Goldberg explains why psychiatry is reclaiming the term "deprescribing" — and what it means for clinicians who want to thoughtfully curate and oversee medication regimens over time. ## Optional - [Sitemap index](https://www.psychiatrist.com/sitemaps/index.xml): every indexable URL, with last-modified dates - [About](https://www.psychiatrist.com/about/)